DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-D-0487]

Guidance for Industry: Implementation of an Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a document entitled "Guidance for Industry: Implementation of an Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma" dated February 2013. The guidance document recognizes the standardized full-length and abbreviated donor history questionnaires and accompanying materials, version 1.2 dated September 2012, as an acceptable mechanism that is consistent with FDA’s requirements and recommendations for collecting Source Plasma donor history information. The Plasma Protein Therapeutics Association (PPTA) Source Plasma donor history questionnaires and accompanying materials (SPDHQ documents) will provide blood establishments that collect Source Plasma with a specific process for administering questions to Source Plasma donors to determine their eligibility to donate. The guidance announced in this notice finalizes the draft guidance of the same title dated July 2011.

DATES: Submit either electronic or written comments on Agency guidances at any time.
ADDRESSES: Submit written requests for single copies of the guidance to the Office of Communication, Outreach and Development (HFM-40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448. Send one self-addressed adhesive label to assist the office in processing your requests. The guidance may also be obtained by mail by calling CBER at 1-800-835-4709 or 301-827-1800. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document.

Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

Tami Belouin,
Center for Biologics Evaluation and Research (HFM-17),
Food and Drug Administration,
1401 Rockville Pike, suite 200N,
Rockville, MD 20852-1448,
301-827-6210.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a document entitled "Guidance for Industry: Implementation of an Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma" dated February 2013. The guidance document recognizes the standardized full-length and abbreviated donor
history questionnaires and accompanying materials, version 1.2 dated September 2012, prepared
by the PPTA, as an acceptable mechanism that is consistent with FDA’s requirements and
recommendations for collecting Source Plasma donor history information. The SPDHQ
documents will provide blood establishments that collect Source Plasma with a specific process
for administering questions to Source Plasma donors to determine their eligibility to donate. The
guidance also advises Source Plasma manufacturers who choose to implement the acceptable
SPDHQ documents on how to report the manufacturing change consisting of the implementation
of the SPDHQ under 21 CFR 601.12.

In the Federal Register of July 22, 2011 (76 FR 44013), FDA announced the availability
of the draft guidance of the same title dated July 2011. FDA received no comments on the draft
guidance. A summary of changes includes: Referencing the most current version of the
acceptable SPDHQ documents, clarifying that the full-length and abbreviated questionnaires are
designed to be implemented together, and making a few editorial changes to improve clarity. The
guidance announced in this notice finalizes the draft guidance dated July 2011.

The guidance is being issued consistent with FDA's good guidance practices regulation
(21 CFR 10.115). The guidance represents FDA's current thinking on this topic. It does not
create or confer any rights for or on any person and does not operate to bind FDA or the public.
An alternative approach may be used if such approach satisfies the requirements of the
applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

This guidance refers to previously approved collections of information found in FDA
regulations. These collections of information are subject to review by the Office of Management
and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR 601.12 have been approved under OMB control number 0910-0338 and the collections of information in 21 CFR 640.63 have been approved under OMB control number 0910-0116.

III. Comments

Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

IV. Electronic Access

Persons with access to the Internet may obtain the guidance at either http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidance/default.htm or http://www.regulations.gov.


Leslie Kux,
Assistant Commissioner for Policy.

[FR Doc. 2013-04384 Filed 02/25/2013 at 8:45 am; Publication Date: 02/26/2013]